513 related articles for article (PubMed ID: 31579904)
1. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
Monteiro P; Bergenstal RM; Toural E; Inzucchi SE; Zinman B; Hantel S; Kiš SG; Kaspers S; George JT; Fitchett D
Age Ageing; 2019 Nov; 48(6):859-866. PubMed ID: 31579904
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME
Kaku K; Lee J; Mattheus M; Kaspers S; George J; Woerle HJ;
Circ J; 2017 Jan; 81(2):227-234. PubMed ID: 28025462
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
Zinman B; Inzucchi SE; Wanner C; Hehnke U; George JT; Johansen OE; Fitchett D;
Diabetologia; 2018 Jul; 61(7):1522-1527. PubMed ID: 29713728
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B
Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757
[TBL] [Abstract][Full Text] [Related]
6. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Inzucchi SE; Zinman B; Fitchett D; Wanner C; Ferrannini E; Schumacher M; Schmoor C; Ohneberg K; Johansen OE; George JT; Hantel S; Bluhmki E; Lachin JM
Diabetes Care; 2018 Feb; 41(2):356-363. PubMed ID: 29203583
[TBL] [Abstract][Full Text] [Related]
7. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
Zinman B; Inzucchi SE; Lachin JM; Wanner C; Ferrari R; Fitchett D; Bluhmki E; Hantel S; Kempthorne-Rawson J; Newman J; Johansen OE; Woerle HJ; Broedl UC
Cardiovasc Diabetol; 2014 Jun; 13():102. PubMed ID: 24943000
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B; Wanner C; Lachin JM; Fitchett D; Bluhmki E; Hantel S; Mattheus M; Devins T; Johansen OE; Woerle HJ; Broedl UC; Inzucchi SE;
N Engl J Med; 2015 Nov; 373(22):2117-28. PubMed ID: 26378978
[TBL] [Abstract][Full Text] [Related]
9. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Inzucchi SE; Fitchett D; Jurišić-Eržen D; Woo V; Hantel S; Janista C; Kaspers S; George JT; Zinman B;
Diabetes Obes Metab; 2020 Apr; 22(4):631-639. PubMed ID: 31789445
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B;
N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675
[TBL] [Abstract][Full Text] [Related]
11. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
12. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Fitchett D; Butler J; van de Borne P; Zinman B; Lachin JM; Wanner C; Woerle HJ; Hantel S; George JT; Johansen OE; Inzucchi SE;
Eur Heart J; 2018 Feb; 39(5):363-370. PubMed ID: 29020355
[TBL] [Abstract][Full Text] [Related]
13. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
14. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
Butler J; Zannad F; Fitchett D; Zinman B; Koitka-Weber A; von Eynatten M; Zwiener I; George J; Brueckmann M; Cheung AK; Wanner C
Circ Heart Fail; 2019 Jun; 12(6):e005875. PubMed ID: 31163986
[TBL] [Abstract][Full Text] [Related]
17. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Schmedt N; Koeneman L; Déruaz-Luyet A; Paik JM; Patorno E
Diabetologia; 2024 Jul; 67(7):1328-1342. PubMed ID: 38509341
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
Kadowaki T; Nangaku M; Hantel S; Okamura T; von Eynatten M; Wanner C; Koitka-Weber A
J Diabetes Investig; 2019 May; 10(3):760-770. PubMed ID: 30412655
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Ferreira JP; Fitchett D; Ofstad AP; Kraus BJ; Wanner C; Zwiener I; Zinman B; Lauer S; George JT; Rossignol P; Zannad F
Am J Hypertens; 2020 Dec; 33(12):1092-1101. PubMed ID: 32369546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
